Literature DB >> 14747546

Small internal deletions in the human cytomegalovirus IE2 gene result in nonviable recombinant viruses with differential defects in viral gene expression.

Elizabeth A White1, Charles L Clark, Veronica Sanchez, Deborah H Spector.   

Abstract

The human cytomegalovirus (HCMV) IE2 86-kDa protein is a key viral transactivator and an important regulator of HCMV infections. We used the HCMV genome cloned as a bacterial artificial chromosome (BAC) to construct four HCMV mutants with disruptions in regions of IE2 86 that are predicted to be important for its transactivation and autoregulatory functions. Three of these mutants have mutations that remove amino acids 356 to 359, 427 to 435, and 505 to 511, which disrupts a region of IE2 86 implicated in the activation of HCMV early promoters, a predicted zinc finger domain, and a putative helix-loop-helix motif, respectively, while the fourth carries three arginine-to-alanine substitution mutations in the region of amino acids 356 to 359. The resulting recombinant viruses are not viable, and by using quantitative real-time reverse transcription-PCR and immunofluorescence we have determined the location of the block in their replicative cycles. The IE2 86 Delta 356-359 mutant is able to support early gene expression, as indicated by the presence of UL112-113 transcripts and UL112-113 and UL44 proteins in cells transfected with the mutant BAC. This mutant does not express late genes and behaves nearly indistinguishably from the IE2 86R356/7/9A substitution mutant. Both exhibit detectable upregulation of major immediate-early transcripts at early times. The IE2 86 Delta 427-435 and IE2 86 Delta 505-511 recombinant viruses do not activate the early genes examined and are defective in repression of the major immediate-early promoter. These two mutants also induce the expression of selected delayed early (UL89) and late genes at early times in the infection. We conclude that these three regions of IE2 86 are necessary for productive infections and for differential control of downstream viral gene expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747546      PMCID: PMC369462          DOI: 10.1128/jvi.78.4.1817-1830.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Human cytomegalovirus IE2 86-kilodalton protein binds p53 but does not abrogate G1 checkpoint function.

Authors:  L R Bonin; J K McDougall
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Cell cycle dysregulation by human cytomegalovirus: influence of the cell cycle phase at the time of infection and effects on cyclin transcription.

Authors:  B S Salvant; E A Fortunato; D H Spector
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome.

Authors:  M Messerle; I Crnkovic; W Hammerschmidt; H Ziegler; U H Koszinowski
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

4.  Identification of domains within the human cytomegalovirus major immediate-early 86-kilodalton protein and the retinoblastoma protein required for physical and functional interaction with each other.

Authors:  E A Fortunato; M H Sommer; K Yoder; D H Spector
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Site-specific inhibition of RNA polymerase II preinitiation complex assembly by human cytomegalovirus IE86 protein.

Authors:  J Wu; R Jupp; R M Stenberg; J A Nelson; P Ghazal
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  The UL84 protein of human cytomegalovirus acts as a transdominant inhibitor of immediate-early-mediated transactivation that is able to prevent viral replication.

Authors:  S Gebert; S Schmolke; G Sorg; S Flöss; B Plachter; T Stamminger
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Evaluation and mapping of the DNA binding and oligomerization domains of the IE2 regulatory protein of human cytomegalovirus using yeast one and two hybrid interaction assays.

Authors:  J H Ahn; C J Chiou; G S Hayward
Journal:  Gene       Date:  1998-03-27       Impact factor: 3.688

8.  Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus ie1 mutant.

Authors:  R F Greaves; E S Mocarski
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Human cytomegalovirus IE86 protein interacts with promoter-bound TATA-binding protein via a specific region distinct from the autorepression domain.

Authors:  R Jupp; S Hoffmann; R M Stenberg; J A Nelson; P Ghazal
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

10.  Identification and mapping of dimerization and DNA-binding domains in the C terminus of the IE2 regulatory protein of human cytomegalovirus.

Authors:  C J Chiou; J Zong; I Waheed; G S Hayward
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

View more
  57 in total

1.  The carboxyl-terminal region of human cytomegalovirus IE1491aa contains an acidic domain that plays a regulatory role and a chromatin-tethering domain that is dispensable during viral replication.

Authors:  Jens Reinhardt; Geoffrey B Smith; Christopher T Himmelheber; Jane Azizkhan-Clifford; Edward S Mocarski
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  The late promoter of the human cytomegalovirus viral DNA polymerase processivity factor has an impact on delayed early and late viral gene products but not on viral DNA synthesis.

Authors:  Hiroki Isomura; Mark F Stinski; Ayumi Kudoh; Sanae Nakayama; Satoko Iwahori; Yoshitaka Sato; Tatsuya Tsurumi
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

3.  The IE2 60-kilodalton and 40-kilodalton proteins are dispensable for human cytomegalovirus replication but are required for efficient delayed early and late gene expression and production of infectious virus.

Authors:  Elizabeth A White; Christia J Del Rosario; Rebecca L Sanders; Deborah H Spector
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

Review 4.  Identification and function of human cytomegalovirus microRNAs.

Authors:  Finn Grey; Jay Nelson
Journal:  J Clin Virol       Date:  2008-03       Impact factor: 3.168

Review 5.  Differences between mouse and human cytomegalovirus interactions with their respective hosts at immediate early times of the replication cycle.

Authors:  Gerd G Maul; Dmitri Negorev
Journal:  Med Microbiol Immunol       Date:  2008-02-09       Impact factor: 3.402

6.  Genus beta human papillomavirus E6 proteins vary in their effects on the transactivation of p53 target genes.

Authors:  Elizabeth A White; Johanna Walther; Hassan Javanbakht; Peter M Howley
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

7.  Human cytomegalovirus early protein pUL21a promotes efficient viral DNA synthesis and the late accumulation of immediate-early transcripts.

Authors:  Anthony R Fehr; Dong Yu
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

8.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

9.  Granzyme M targets host cell hnRNP K that is essential for human cytomegalovirus replication.

Authors:  R van Domselaar; S A H de Poot; E B M Remmerswaal; K W Lai; I J M ten Berge; N Bovenschen
Journal:  Cell Death Differ       Date:  2012-10-26       Impact factor: 15.828

10.  A cis element between the TATA Box and the transcription start site of the major immediate-early promoter of human cytomegalovirus determines efficiency of viral replication.

Authors:  Hiroki Isomura; Mark F Stinski; Ayumi Kudoh; Sanae Nakayama; Takayuki Murata; Yoshitaka Sato; Satoko Iwahori; Tatsuya Tsurumi
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.